FDA OKs Long-Acting Risperidone; TMS for Anxious Depression; CBT Bests Pharma

The FDA approved the biweekly long-acting injectable (LAI) risperidone (Rykindo) for the treatment of schizophrenia and bipolar I disorder, Luye Pharma Group announced.

A phase IIa study showed a significantly greater improvement in Montgomery-Åsberg Depression Rating Scale score with the potential first-in-class investigational treatment ALTO-100 among a group of patients with biomarker-defined major depressive disorder, said developer Alto Neuroscience.

Practicing deep meditation on a regular basis can help reduce the risks of anxiety, depression, and cardiovascular disease by regulating the gut microbiome, according to a study of Tibetan Buddhist monks. (General Psychiatry)

Neuronetics released new data showing significant symptom improvement in people with anxious depression following treatment with its NeuroStar transcranial magnetic stimulation device (TMS), though these patients still had lower responses and remission rates than those with non-anxious depression. (Journal of Clinical Psychiatry)

Military veterans experiencing an “acute suicidal crisis” are now eligible for free treatment, including both inpatient and outpatient care. (U.S. Department of Veterans Affairs)

In a meta-analysis of 409 trials, cognitive behavioral therapy (CBT) was found to be just as effective as pharmacotherapies for depression in the short term, and even more effective long term. (World Psychiatry)

For pregnant women with opioid use disorder, treatment with buprenorphine-naloxone (Suboxone) was safe for neonates. (Acta Obstetricia et Gynecologica Scandinavica)

A St. Louis psychiatrist and his firm were ordered to pay $5 million to the family of a patient who died after allegedly being overprescribed lisdexamfetamine (Vyvanse) for ADHD. (St. Louis Post-Dispatch)